Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

8.49
+0.50806.37%
Post-market: 8.490.00000.00%19:17 EDT
Volume:2.52K
Turnover:20.87K
Market Cap:33.64M
PE:-2.25
High:8.49
Open:8.37
Low:8.18
Close:7.98
Loading ...

Mink Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Mink Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

THOMSON REUTERS
·
04 Mar

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

GlobeNewswire
·
04 Mar

Health Check:  Half-price sale as brokers ring the bell on Neuren shares

Stockheads
·
04 Mar

Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating

TIPRANKS
·
25 Feb

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
24 Feb

Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
20 Feb

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
13 Feb

Mink Therapeutics Inc trading halted, news pending

TIPRANKS
·
28 Jan

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

GlobeNewswire
·
24 Jan

Mink Therapeutics Inc - to Effect 1-for-10 Reverse Stock Split

THOMSON REUTERS
·
22 Jan

Dr Boreham’s Crucible: This cancer-tackling, cell-therapy player might just have a fighting chance

Stockheads
·
07 Jan

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

GlobeNewswire
·
18 Dec 2024

Health Check: No sign of frayed nerves as Orthocell girds for US approval

Stockheads
·
02 Dec 2024

Q3 2024 Mink Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
15 Nov 2024